Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
logo icon CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
News and Events

Featured Stories

Hot information:
Top 10 Global Clinical Research Organizations in 2021| Medicilon Pharmacokinetic Services for First-in-Class Ubiquitination Inhibitor Development| ADC, precision and deep cultivation for targeted drug delivery
Sep 09,2022
ADC Drug Research Report
The design idea of ADC drugs is to couple antibodies with cytotoxic drugs, so as to simultaneously exert the high specificity of antibodies and the high toxicity of cytotoxic small molecules.
More
ADC Drug Research Report
Sep 08,2022
Birth, Development and Prospect of ADC Drugs
ADC (antibody-conjugated drug) is not a new concept. As the early 20th century, the Nobel Prize winner in medicine, German scientist Paul Ehrlich, had proposed the concept of ADC and called ADC drugs " Magic Bullet". But it wasn't until the 1950s that research on ADC drugs took off.
More
Birth, Development and Prospect of ADC Drugs
Sep 07,2022
HER2 ADC Terminator?
If there were pharmaceutical companies involved in making PD-1 antibodies before 2012, they might have become companies with a valuation of tens of billions by now.
More
HER2 ADC Terminator?
Sep 06,2022
The ADC drug industry is thriving!
Medicilon has rich experience in developing and validating analysis methods for different targets, and can effectively analyze the expression level and accessibility of targets according to needs, and provide constructive suggestions for target selection.
More
The ADC drug industry is thriving!
Sep 02,2022
ALK inhibitors: iterative upgrade, targeted therapies strike with precision
Fourth-generation ALK inhibitors are currently under investigation. Biomedical technology is constantly advancing and drug development is constantly evolving. Medicilon has established a one-stop platform for preclinical biopharmaceutical R&D services, including drug discovery, pharmacological research, and preclinical research.
More
ALK inhibitors: iterative upgrade, targeted  therapies strike with precision
Aug 30,2022
ADC drug interpretation (4) | ADC market situation and competitive landscape
In recent years, the global ADC drug R&D and investment has been escalating. With the advancement of technology, ADC has not only broken through the classic antibody + linker + small molecule toxin model in structure, but also become a new type of ADC drugs.
More
ADC drug interpretation (4) | ADC market situation and competitive landscape
Aug 29,2022
Interpretation of ADC drugs (3) | An article to analyze the difficulties of ADC drug development
The complex and diverse structure of ADC drugs, as well as the complexities of in vivo actions and metabolic processes, bring multiple challenges to CMC research and preclinical research.
More
Interpretation of ADC drugs (3) | An article to analyze the difficulties of ADC drug development
Aug 26,2022
What is the subtleties of Antibody-drug conjugates
Antibody-drug conjugates (ADCs) have been the focus of tumor therapy research in recent years. The mechanism of action of ADC is complex and usually requires drug internalization followed by intracellular processing and payload release.
More
What is the subtleties of Antibody-drug conjugates
Aug 01,2022
ADC, precision and deep cultivation for targeted drug delivery
Antibody conjugate (ADC) is the focus of tumor therapy research in recent years. Because of its good targeting and obvious clinical efficacy, ADC has become the frontier of antibody drug research and development and is one of the strategic focuses of new drug research and development in China.
More
ADC, precision and deep cultivation for targeted drug delivery
Aug 01,2022
CGeneTech's Class 1 innovative drug CGT-9475 has achieved dual application and approval in China and the US with the help of Medicilon's one-stop preclinical pharmaceutical R&D service platform
On July 22, CGT-9475, a new generation of ALK inhibitor independently developed by CGeneTech (Suzhou, China) Co., Ltd. (CGeneTech), was approved by the US Food and Drug Administration (FDA) to enter the clinical trial.
More
CGeneTech's Class 1 innovative drug CGT-9475 has achieved dual application and approval in China and the US with the help of Medicilon's one-stop preclinical pharmaceutical R&D service platform